Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $98 to $102.
Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $98 to $102.